XOLAIR® 150mg (non-English)
$599.00
XOLAIR® 150 mg (Non-English Packaging) contains omalizumab, a recombinant monoclonal antibody designed to target immunoglobulin E (IgE)—a key driver of allergic reactions. It is administered via subcutaneous injection under specialist supervision.
In Stock
Description
XOLAIR® is indicated for:
- Moderate to severe persistent allergic asthma
- Chronic spontaneous urticaria (chronic hives)
- Chronic rhinosinusitis with nasal polyps
It is typically used in patients who remain symptomatic despite standard therapies.
Key Product Insights:
- Omalizumab anti-IgE monoclonal antibody
- Targets allergic inflammation pathways
- Treats asthma, urticaria, nasal polyps
- Reduces IgE-mediated immune response
- Subcutaneous biologic injection therapy
- Improves symptom control and quality of life
- Clinically proven long-term efficacy
Related products
This error message is only visible to WordPress admins
Error: No feed found.
Please go to the Instagram Feed settings page to create a feed.
Reviews
There are no reviews yet.